Alginate Microsphere as a Delivery System and Adjuvant forAutoclaved Leishmania majorand Quillaja Saponin: Preparationand Characterization Microspheres for antigen delivery
Iranian Journal of Pharmaceutical Sciences,
Vol. 3 No. 2 (2007),
1 Farvardin 2007
,
Page 61-68
https://doi.org/10.22037/ijps.v3.40340
Abstract
The goal of this study was to prepare and characterize alginate microspheres asan antigen delivery system and adjuvant for immunization against leishmaniasis.Microspheres encapsulated with autoclaved Leishmania major(ALM) and Quillajasaponin (QS) were prepared by an emulsification technique and characterized forsize, encapsulation efficiency and release profile of encapsulates. Selection ofappropriate parameters (viscosity of alginate, emulsifier and sonication times)enabled the preparation of alginate microspheres with a mean diameter of 1.92±1.0μm, as determined by scanning electron microscopy and particle size analyzer. Theencapsulation efficiency was about 34.2±6.7% for ALM and 31.0±4.4% for QS, asdetermined by spectrophotometric assays.In vitro release profile showed a slowrelease rate for encapsulated ALM and QS, 35.7±8.7% of ALM and 36.9±4.7% ofQS were released during 1 week. The molecular weight was evaluated by SDS-PAGEand showed that the process of encapsulation did not affect the molecular weightof the entrapped antigen. With regard to the optimum diameter (less than 5 m), slowrelease rate and preservation of antigen molecules, formulated alginate microspherescould be considered as a promising antigen delivery system and adjuvant for ALMand QS.
- Adjuvant
- Alginate microsphere
- Immunization
- Leishmania major
- Leishmaniasis
- Quillaja saponins
How to Cite
References
[2]Modabber F. Vaccines against leishmaniasis. AnnTrop Med Parasitol 1995; 89: 83-8.
[3]Frankenburg S, Axelrod O, Kutner S, GreenblattCL, Klaus SN, Pirak EA, McMaster R, LowellGH. Effective immunization of mice againstcutaneous leishmaniasis using an intrinsicallyadjuvanted synthetic lipopeptide vaccine. Vaccine1996; 14: 923-9.
[4]Follador I, Araujo C, Orge G, Cheng LH, deCarvalho LP, Bacellar O, Almeida RP, CarvalhoEM. Immune responses to an inactive vaccineagainst American cutaneous leishmaniasistogether with granulocyte-macrophage colony-stimulating factor.Vaccine 2002; 20: 1365-8.
[5]Satti IN, Osman HY, Daifalla NS, Younis SA,Khalil EA, Zijlstra EE, El Hassan AM, GhalibHW. Immunogenicity and safety of autoclavedLeishmania major plus BCG vaccine in healthySudanese volunteers. Vaccine2001; 19: 2100-6.
[6]Fundueanu G, Esposito E, Mihai D, Carpov A,Desbrieres J, Rinaudo M, Nastruzzi C. Preparationand characterization of Ca-alginate microspheresby a new emulsification method. Int J Pharm1998; 170: 11-21.[7]Lemoine D, Wauters F, Bouchend'homme S, PreatV. Preparation and characterization of alginatemicrospheres containing a model antigen. Int JPharm1998; 176: 9-19.
[8]Tafaghodi M, Jaafari MR, Sajadi Tabasi SA.Nasal immunization studies by liposomesencapsulated with tetanus toxoid and CpG-ODN.Eur J Pharm Biopharm2006; 64: 138-45.
[9]Mittal SK, Aggarwal N, Sailaja G, van Olphen A,HogenEsch H, North A, Hays J, Moffatt S.Immunization with DNA, adenovirus or both inbiodegradable alginate microspheres: Effect ofroute of inoculation on immune response. Vaccine2000; 19: 253-63.
[10]Ellis JA, West KH, Waldner C, Rhodes C. Efficacyof a saponin-adjuvanted inactivated respiratorysyncytial virus vaccine in calves. Canadian Vet J2005; 46: 155-62.
[11]Zhang P, Yang Q-B, Marciani DJ, Martin M,Clements JD, Michalek SM, Katz J. Effectivenessof the quillaja saponin semi-synthetic analogGPI-0100 in potentiating mucosal and systemicresponses to recombinant HagB fromPorphyromonas gingivalis. Vaccine2003; 21:4459-71.
[12]Huber M, Baier W, Bessler WG, Heinevetter L.Modulation of the Th1/Th2 bias by lipopeptideand saponin adjuvants in orally immunized mice.Immunobiology2002; 205: 61-73.
[13]Lacaille-Dubois MA. Saponins as immunoadju-vants and immunostimulants. In: Wagner H,(editor). Immunomodulatory agents from plants.Switzerland: Birkhauser Verlag, 1999; pp. 243-72.
[14]Cox JC, Coulter AR. Adjuvants: a classificationand review of their modes of action. Vaccine1997; 15: 248-56.
[15]Gupta RK, Siber GR. Adjuvants for humanvaccines: Current status, problems and futureprospects. Vaccine1995; 13: 1263-76.
[16]Singh M, O'Hagan D. Advances in vaccineadjuvants.Nat Biotechnol1999; 17: 1075-81.
[17]Diwan M, Tafaghodi M, Samuel J. Enhancementof immune responses by co-delivery of a CpGoligodeoxynucleotide and tetanus toxoid inbiodegradable nanospheres. J Control Release2002; 85: 247-62.[18]Tafaghodi M, Sajadi Tabasi SA, Jaafari MR.Induction of systemic and mucosal immuneresponses by intranasal administration of alginatemicrospheres encapsulated with tetanus toxoid andCpG-ODN. Int J Pharm 2006; 319: 37-43.
[19]Tafaghodi M, Sajadi Tabasi SA, Jaafari MR.Formulation and characterization and releasestudies of alginate microsphere encapsulated withtetanus toxoid. J Biomat Sci Polymer Ed 2006; 17:909-24.[20]Waterborg JH. Quantitation of proteins. In:Walker J, (editor). The protein protocolshandbook. 2nd ed. Newjersey: Humana Press,2002; pp. 3-36.
[21]Rebelatto MC, Guimond P, Bowersock TL, HogenEsch H. Induction of systemic and mucosalimmune response in cattle by intranasaladministration of pig serum albumin in alginatemicroparticles. Vet Immunol Immunopathol2001;83: 93-105.
[22]Tafaghodi M, Sajadi Tabassi SA, Jaafari MR.Induction of systemic and mucosal immuneresponses by intranasal administration of alginatemicrospheres encapsulated with tetanus toxoid andCpG-ODN. Int J Pharm2006; 319: 37-43.
[23]Sinha VR, Trehan A. Biodegradable microspheresfor protein delivery. J Control Release2003; 90:261-80.
[24]Mutwiri G, Bowersock T, Kidane A, Sanchez M,Gerdts V, Babiuk LA, Griebel P. Induction ofmucosal immune responses following entericimmunization with antigen delivered in alginatemicrospheres. Vet Immunol Immunopathol2002;87: 269-76.
[25]Kim B, Bowersock T, Griebel P, Kidane A, BabiukLA, Sanchez M, Attah-Poku S, Kaushik RS,Mutwiri GK. Mucosal immune responsesfollowing oral immunization with rotavirusantigens encapsulated in alginate microspheres.J Control Release 2002; 85: 191-202.
[26]Cho N-H, Seong S-Y, Chun K-H, Kim Y-H, ChanKwon I, Ahn B-Y, Jeong SY. Novel mucosalimmunization with polysaccharide-proteinconjugates entrapped in alginate microspheres. JControl Release1998; 53: 215-24.
[27]Bowersock TL, HogenEsch H, Torregrosa S,Della Borie, Wang B, Park H, Park K. Inductionof pulmonary immunity in cattle by oraladministration of ovalbumin in alginatemicrospheres. Immunol Lett1998; 60: 37-43.
[28]Ghiasi Z, Sajadi Tabasi SA, Tafaghodi M.Preparation and characterization of alginatemicrospheres encapsulated with autoclavedLeishmania major(ALM) and CpG-ODN.Iranian J Basic Med Sci2007; In Press.[29]Al-Musa S, Abu Fara D, Badwan AA. Evaluationof parameters involved in preparation and releaseof drug loaded in crosslinked matrices of alginate.J Control Release1999; 57: 223-32.
[30]Freiberg S, Zhu XX. Polymer microspheres forcontrolled drug release. Int J Pharm2004; 282:1-18.
[31]Freitas S, Merkle HP, Gander B. Microencapsu-lation by solvent extraction/evaporation:reviewing the state of the art of microspherepreparation process technology. J Control Release2005; 102: 313-32.[32]Kahl LP, Lelchuk R, Scott CA, Beesley J. Char-acterization of Leishmania majorantigen-liposomes that protect BALB/c miceagainst cutaneous leishmaniasis.Infect Immun1990; 58: 3233-41.
- Abstract Viewed: 97 times
- IJPS_Volume 3_Issue 2_Pages 61-68 Downloaded: 16 times